Glimepiride Eg (Glimepiride)

Glimepiride EG is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, usually as part of a comprehensive treatment plan that includes diet and exercise.

• Used as monotherapy when diet, exercise, and weight control are insufficient.
• Combined with other oral antidiabetic agents such as metformin to achieve target glycemic levels.
• May be prescribed after other sulfonylureas have been ineffective or not tolerated.
• Adjusted based on renal function and individual response to therapy.
• Considered for patients who require a once‑daily oral agent to simplify dosing.

The safety profile of glimepiride includes a range of adverse events that are categorized by frequency and severity.

Common

• Low blood sugar (hypoglycemia), especially if meals are missed.
• Weight gain due to increased insulin activity.
• Nausea or mild gastrointestinal discomfort.
• Headache or dizziness.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Allergic reactions such as rash, itching, or swelling.
• Hepatic dysfunction indicated by elevated liver enzymes.

Before initiating glimepiride EG, clinicians should evaluate several patient‑specific factors to minimize risks and ensure appropriate use.

• Assess renal and hepatic function; dose adjustments may be required in impairment.
• Review history of hypoglycemia or adrenal insufficiency, as these increase risk.
• Use with caution in elderly patients due to heightened sensitivity to low blood glucose.
• Avoid use during pregnancy and breastfeeding unless benefits clearly outweigh risks.
• Monitor blood glucose regularly, especially after dose changes or when adding other medications.
• Consider cardiovascular status, as sulfonylureas may affect cardiac repolarization in susceptible individuals.

Glimepiride EG can interact with several drug classes, altering its glucose‑lowering effect or increasing the likelihood of adverse reactions.

Avoid

• Concurrent use with other sulfonylureas or insulin, which can cause profound hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glimepiride plasma concentrations.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may potentiate hypoglycemic episodes.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, as they can affect blood glucose control.
• Oral contraceptives and hormone replacement therapy, which may modify drug metabolism.